Moomoo AI 已提取核心信息
Johnson & Johnson, the New Jersey-based healthcare giant, has announced its definitive agreement to acquire Ambrx Biopharma, Inc., as detailed in a presentation during a town hall with Ambrx employees on February 15, 2024. The acquisition is subject to closing conditions, including antitrust clearances and approval by Ambrx stockholders. Johnson & Johnson cautions that forward-looking statements regarding the acquisition should not be relied upon due to potential risks and uncertainties that could affect the outcome. These include the possibility that the transaction may not be completed as expected, adverse effects on the businesses during the pendency of the transaction, and challenges in integrating Ambrx into Johnson & Johnson's operations. The definitive proxy statement for the proposed transaction was filed with the SEC on January 29, 2024, and mailed to Ambrx stockholders of record as of February 2, 2024. Investors and stockholders are urged to read the relevant documents filed with the SEC for important information about the acquisition.
Johnson & Johnson, the New Jersey-based healthcare giant, has announced its definitive agreement to acquire Ambrx Biopharma, Inc., as detailed in a presentation during a town hall with Ambrx employees on February 15, 2024. The acquisition is subject to closing conditions, including antitrust clearances and approval by Ambrx stockholders. Johnson & Johnson cautions that forward-looking statements regarding the acquisition should not be relied upon due to potential risks and uncertainties that could affect the outcome. These include the possibility that the transaction may not be completed as expected, adverse effects on the businesses during the pendency of the transaction, and challenges in integrating Ambrx into Johnson & Johnson's operations. The definitive proxy statement for the proposed transaction was filed with the SEC on January 29, 2024, and mailed to Ambrx stockholders of record as of February 2, 2024. Investors and stockholders are urged to read the relevant documents filed with the SEC for important information about the acquisition.
总部位于新泽西州的医疗保健巨头强生公司宣布了收购Ambrx Biopharma, Inc. 的最终协议，详情见2024年2月15日在市政厅与Ambrx员工举行的演讲。此次收购受成交条件的约束，包括反垄断许可和Ambrx股东的批准。强生公司警告说，由于可能影响结果的潜在风险和不确定性，因此不应依赖有关收购的前瞻性陈述。其中包括交易可能无法按预期完成，在交易悬而未决期间对业务造成的不利影响，以及将Ambrx纳入强生公司的业务所面临的挑战。拟议交易的最终委托书已于2024年1月29日向美国证券交易委员会提交，并邮寄给截至2024年2月2日的Ambrx登记股东。我们敦促投资者和股东阅读向美国证券交易委员会提交的相关文件，以获取有关此次收购的重要信息。
总部位于新泽西州的医疗保健巨头强生公司宣布了收购Ambrx Biopharma, Inc. 的最终协议，详情见2024年2月15日在市政厅与Ambrx员工举行的演讲。此次收购受成交条件的约束，包括反垄断许可和Ambrx股东的批准。强生公司警告说，由于可能影响结果的潜在风险和不确定性，因此不应依赖有关收购的前瞻性陈述。其中包括交易可能无法按预期完成，在交易悬而未决期间对业务造成的不利影响，以及将Ambrx纳入强生公司的业务所面临的挑战。拟议交易的最终委托书已于2024年1月29日向美国证券交易委员会提交，并邮寄给截至2024年2月2日的Ambrx登记股东。我们敦促投资者和股东阅读向美国证券交易委员会提交的相关文件，以获取有关此次收购的重要信息。
有用
没用